ARTICLE | Company News
SkyePharma extends Bioglan deal
January 4, 2001 8:00 AM UTC
SkyePharma (LSE:SKP; SKYE) granted Bioglan (LSE:BGP) marketing rights in the U.S., Canada, and Mexico for Solaraze, a topical treatment for actinic keratosis. SKP received a signing fee of $14 million...